your market intelligence analyst
Search Results
24 results
Your search is now limited to «Gilead» expert search.
ENDPOINTS 10/08/2019 11:27
Gilead has been of its rival AbbVie with its JAK-inhibitor filgotinib . The company an NDA for the drug to the Japanese Ministry of Health, Labor and Welfare for the treatment of adults with rheumatoid arthritis (RA). The submission is backed by data from the phase III FINCH trial, where “once-daily treatment with filgotinib demonstrated the potential to improve clinical signs and symptoms, to achieve low disease activity and remission and to inhibit structural damage for patients living with RA.”→ After being — on the grounds of manufacturing issues — for its implanted diabetes drug/device ITCA 650 , Intarcia Therapeutics that the FDA has accepted its resubmission of its NDA for ITCA 650 to treat type 2 diabetes mellitus, and set a PDUF.

Financial Services

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Information Technologies

Job Titles

Legal and Regulatory

Political Entities


Strategic Scenarios



  • Actions
    • Bookmark and Share: Allows you to Bookmark the page for easy future retrieval and sharing with colleagues
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • Previous Versions: Only shown if essentially the same document has been republished
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Save" button to the right of the search box. 

Click here for more info on Search Results.